FDA formally approves Gilead’s Veklury for young children


The Food and Drug Administration said Monday it expanded the approval of Gilead Sciences Inc.’s GILD, +0.64% Veklury to include pediatric patients between the ages of four weeks and 12 years old. (Infants must also weigh at least seven pounds.) Veklury is a COVID-19 treatment for patients who have been hospitalized or who have mild or moderate infections but are at high risk of severe COVID-19. The drug previously received emergency authorization for this group of pediatric patients. “As COVID-19 can cause severe illness in children, some of whom do not currently have a vaccination option, there continues to be a need for safe and effective COVID-19 treatment options for this population,” Patrizia Cavazzoni, director of the FDA’s Center for Drug Evaluation and Research, said in a news release. Gilead’s stock is down 14.7% this year, while the broader S&P 500 SPX, +0.57% has declined 10.3%.

This article was originally published by Marketwatch.com. Read the original article here.

Previous articleThe Moneyist: ‘I don’t believe servers should make $50 an hour. They get paid as much as nurses!’ If a waiter is making $15 an hour in California, do I really need to tip 20%?
Next articleNovartis posts higher net profit of $2.22 billion on sales of $12.53 billion


Please enter your comment!
Please enter your name here